Claims
- 1. An isolated polynucleotide comprising a member selected from the group consisting of:
(a) a polynucleotide having at least a 70% identity to a polynucleotide encoding a polypeptide comprising amino acids 1 to 380 of SEQ ID NO:2; (b) a polynucleotide having at least a 70% identity to a polynucleotide encoding a polypetide comprising amino acids 22 to 380 of SEQ ID NO: 2; (c) a polynucleotide which is complementary to the polynucleotide of (a) or (b); and (c) a polynucleotide comprising at least 15 bases of the polynucleotide of (a), (b) or (c).
- 2. The polynucleotide of claim 1 wherein the polynucleotide is DNA.
- 3. The polynucleotide of claim 1 wherein the polynucleotide is RNA.
- 4. The polynucleotide of claim 2 comprising nucleotides 1 to 1288 set forth in SEQ ID NO:1.
- 5. The polynucleotide of claim 2 comprising nucleotides 31 to 1170 set forth in SEQ ID NO:1.
- 6. The polynucleotide of claim 2 which encodes a polypeptide comprising amino acids 1 to 380 of SEQ ID NO:2.
- 7. The polynucleotide of claim 2 which encodes a polypeptide comprising amino acids 22 to 380 of SEQ ID NO:2.
- 8. An isolated polynucleotide comprising a member selected from the group consisting of:
(a) a polynucleotide having at least a 70% identity to a polynucleotide encoding the same mature polypeptide expressed by the human cDNA contained in ATCC Deposit No. 98069; (b) a polynucleotide complementary to the polynucleotide of (a); and (c) a polynucleotide comprising at least 15 bases of the polynucleotide of (a) or (b).
- 9. A vector comprising the DNA of claim 2.
- 10. A host cell comprising the vector of claim 9.
- 11. A process for producing a polypeptide comprising: expressing from the host cell of claim 10 a polypeptide encoded by said DNA.
- 12. A process for producing a cell which expresses a polypeptide comprising transforming or transfecting the cell with the vector of claim 9 such that the cell expresses the polypeptide encoded by the human cDNA contained in the vector.
- 13. A polypeptide comprising an amino acid sequence which is at least 70% identical to amino acid 1 to 380 of SEQ ID NO:2.
- 14. A polypeptide comprising an amino acid sequence which is at least 70% identical to amino acid 22 to 380 of SEQ ID NO:2.
- 15. A polypeptide comprising an amino acid sequence 1 to 380 as set forth in SEQ ID NO:2.
- 16. A polypeptide comprising an amino acid sequence 22 to 380 as set forth in SEQ ID NO:2.
- 17. An agonist to the polypeptide of claim 13, 14, 15 or 16.
- 18. An antibody against the polypeptide of claim 13, 14, 15 or 16.
- 19. An antagonist which inhibits the activity of the polypeptide of claim 13, 14, 15 or 16.
- 20. A method for the treatment of a patient having need of HR-1 RECEPTOR comprising: administering to the patient a therapeutically effective amount of the polypeptide of claim 13, 14, 15 or 16.
- 21. The method of claim 20 wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide in vivo.
- 22. A method for the treatment of a patient having need to inhibit HR-1 RECEPTOR polypeptide comprising: administering to the patient a therapeutically effective amount of the antagonist of claim 19.
- 23. A process for diagnosing a disease or a susceptibility to a disease related to expression of the polypeptide of claim 13, 14, 15 or 16 comprising:
determining a mutation in the nucleic acid sequence encoding said polypeptide.
- 24. A diagnostic process comprising:
analyzing for the presence of the polypeptide of claim 13, 14, 15 or 16 in a sample derived from a host.
- 25. A method for identifying compounds which bind to and activate or inhibit a receptor for the polypeptide of claim 13, 14, 15 or 16 comprising:
contacting a cell expressing on the surface thereof a receptor for the polypeptide, said receptor being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said receptor, with a compound to be screened under conditions to permit binding to the receptor; and determining whether the compound binds to and activates or inhibits the receptor by detecting the presence or absence of a signal generated from the interaction of the compound with the receptor.
- 26. An isolated nucleic acid molecule comprising a polynucleotide selected from the group consisting of:
(a) a polynucleotide encoding amino acid residues 1 to 380 of SEQ ID NO:2; (b) a polynucleotide encoding amino acid residues 2 to 380 of SEQ ID NO:2; (c) a polynucleotide encoding amino acid residues 22 to 380 of SEQ ID NO:2; (d) a polynucleotide encoding the amino acid sequence of the full-length polypeptide, which amino acid sequence is encoded by the cDNA clone contained in ATCC Deposit No. 98069; (e) a polynucleotide encoding the amino acid sequence of the full-length polypeptide, excluding the N-terminal methionine residue, which amino acid sequence is encoded by the cDNA clone contained in ATCC Deposit No. 98069; (f) a polynucleotide encoding the amino acid sequence of the mature polypeptide, which amino acid sequence is encoded by the cDNA clone contained in ATCC Deposit No. 98069; (g) a polynucleotide encoding amino acid residues 70 to 90 of SEQ ID NO:2; (h) a polynucleotide encoding amino acid residues 100 to 113 of SEQ ID NO:2; (i) a polynucleotide encoding at least 30 contiguous amino acid residues of SEQ ID NO:2; and (j) at least 30 contiguous nucleotides of SEQ ID NO:1.
- 27. The isolated nucleic acid molecule of claim 26 wherein said polynucleotide is (a).
- 28. The isolated nucleic acid molecule of claim 26 wherein said polynucleotide is (b).
- 29. The isolated nucleic acid molecule of claim 26 wherein said polynucleotide is (c).
- 30. The isolated nucleic acid molecule of claim 26 wherein said polynucleotide is (d).
- 31. The isolated nucleic acid molecule of claim 26 wherein said polynucleotide is (e).
- 32. The isolated nucleic acid molecule of claim 26 wherein said polynucleotide is (f).
- 33. The isolated nucleic acid molecule of claim 26 wherein said polynucleotide is (g).
- 34. The isolated nucleic acid molecule of claim 26 wherein said polynucleotide is (h).
- 35. The isolated nucleic acid molecule of claim 26 wherein said polynucleotide is (i).
- 36. The isolated nucleic acid molecule of claim 26 wherein said polynucleotide is (j).
- 37. The isolated nucleic acid molecule of claim 26 wherein the polynucleotide further comprises a heterologous polynucleotide.
- 38. The isolated nucleic acid molecule of claim 37 wherein said heterologous polynucleotide encodes a heterologous polypeptide.
- 39. The isolated nucleic acid molecule of claim 38 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
- 40. A recombinant vector comprising the isolated nucleic acid molecule of claim 26.
- 41. The recombinant vector of claim 40 wherein the nucleic acid molecule is operably associated with a heterologous regulatory sequence that controls gene expression.
- 42. A method of producing a recombinant vector comprising inserting the isolated nucleic acid molecule of claim 26 into a vector.
- 43. A recombinant host cell comprising the isolated nucleic acid molecule of claim 26.
- 44. The recombinant host cell of claim 43 wherein the nucleic acid molecule is operably associated with a heterologous regulatory sequence that controls gene expression.
- 45. A recombinant host cell comprising the recombinant vector of claim 40.
- 46. A method of producing a host cell comprising transducing, transforming or transfecting a host cell with the recombinant vector of claim 40.
- 47. A method for producing a protein, comprising:
(a) culturing a recombinant host cell comprising the isolated nucleic acid molecule of claim 26 under conditions suitable to produce the protein encoded by said nucleic acid molecule; and (b) recovering the protein from the cell culture.
- 48. A composition comprising the polynucleotide of claim 26 and a pharmaceutically acceptable carrier.
RELATED APPLICATIONS
[0001] This application is a continuation of and claims priority under 35 U.S.C. §120 to U.S. patent application Ser. No. 08/871,122, filed Jun. 9, 1997, which claims benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 60/017,843, filed Jun. 12, 1996.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60017843 |
Jun 1996 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
08871122 |
Jun 1997 |
US |
Child |
09871617 |
Jun 2001 |
US |